الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
Cerebral microbleeds are a neuroimaging biomarker, common in ischemic stroke which increase the rate of future intracranial haemorrhage or recurrent ischaemic stroke In this study, there had been an attempt to document the prevalence of CMBs in patients with AIS, recurrent stroke or TIA at Assiut university hospital with 400 patients participated in the study Based on the current study 106 (26.5%) patients had cerebral microbleeds. As regard clinical and demographic data; CMBs were more common among older age (> 60 year) Use of thrombolytic agents is the most powerful predictor followed by Fazekas score > 2, use of aspirin with anticoagulants, use of dual aniplatelets, and age exceeded 60 yearsAn increase in CMBs is also associated with AF, hypertension, dyslipidemia, recurrent stroke and respectively According to antithrombotic therapy, we found that use of dual antiplatelets lead to more prevelance of CMBs than anticoagulants. Accordingly, use of combination of antiplatelet and anticoagulant icreasing risk of prevelance of CMBs . Also hemorrhagic transformation is most common with thrombolytic therapy then combination of antiplatelet and anticoagulant followed by dual antiplatelets Based on the current study, the most frequent locations of the CMBs were deep, probably due to hypertensive microangiopathy or arteriolosclerosis affecting vessel walls and associated with the traditional vascular risk factors, especially arterial hypertension (AHT) Also, we found that increased numbers or grade of CMBs are associated with more WMHL increasing risk of more bleeding. Our results suggest that elderly hypertensive AF ischemic stroke patients maintained on antithrombotic therapy or received alteplase should be screened for the incidence of CMBs and monitored regularly for the development of intracerebral hemorrhage. Further prospective studies are required to define the risk factors for the development of CMBs and to set strategies for prevention of CMBs and consequent neurologic disorders including symptomatic stroke and dementia.